Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00979251 · ClinicalTrials.gov registry record · Phase 2

Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects

A Phase 2 study of Influenza, sponsored by Adamas Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
2
Enrollment target
20
Study locations

NCT00979251: Completed Phase 2 study of Influenza, sponsored by Adamas Pharmaceuticals.

NCT00979251 is a Phase 2 study of Influenza that has completed, run by Adamas Pharmaceuticals. The registered enrollment target is 2 participants, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00979251, a Phase 2 study of Influenza, has completed, sponsored by Adamas Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
2 participants
Enrollment target
20
Study locations

Study Summary

This Phase 2, open label, randomized study will investigate the virologic benefit, clinical efficacy, safety, and tolerability of amantadine and ribavirin with oseltamivir (TCAD) versus oseltamivir monotherapy for the treatment of all strains of influenza A in immunocompromised adult and pediatric subjects.

Conditions Studied

Influenza

Interventions

  • DRUG Oseltamivir Phosphate
  • DRUG ADS-8902

Study Locations (20)

California

  • Adamas Investigational Site - San Francisco
  • Adamas Investigational Site - San Francisco
  • Adamas Investigational Site - San Francisco

Florida

  • Adamas Investigational Site - Hollywood
  • Adamas Investigational Site - Miramar
  • Adamas Investigational Site - Pinellas Park

New South Wales

  • Adamas Investigational Site - Darlinghurst
  • Adamas Investigational Site - Herston
  • Adamas Investigational Site - Sydney

Washington

  • Adamas Investigational Site - Seattle
  • Adamas Investigational Site - Tacoma

Hawaii

  • Adamas Investigational Site - Honolulu

Kentucky

  • Adamas Investigational Site - Owensboro

Louisiana

  • Adamas Investigational Site - New Orleans

Nevada

  • Adamas Investigational Site - Las Vegas

Trial Details

FieldValue
Enrollment Target 2 participants
Start Date 2009-09
Est. Completion 2011-08
Phase Phase 2
Adamas Pharmaceuticals

10 total trials

What the finished NCT00979251 record still lists

NCT00979251 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 2 interventions - of which Oseltamivir Phosphate is the first listed.

NCT00979251 names 20 study sites across 13 states, led by California, Florida, New South Wales.

Frequently Asked Questions

What is clinical trial NCT00979251 about?

NCT00979251 is a clinical study titled "Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects". This Phase 2, open label, randomized study will investigate the virologic benefit, clinical efficacy, safety, and tolerability of amantadine and ribavirin with oseltamivir (TCAD) versus oseltamivir monotherapy for the treatment of all strains of influenza A in immunocompromised adult and pediatric s...

What is the current status of trial NCT00979251?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2009-09. Estimated completion is 2011-08.

What conditions does trial NCT00979251 study?

This clinical trial studies the following conditions: Influenza.

What interventions are being tested in trial NCT00979251?

The interventions under investigation include: Oseltamivir Phosphate (DRUG), ADS-8902 (DRUG).

Who is sponsoring clinical trial NCT00979251?

This trial is sponsored by Adamas Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00979251 being conducted?

This trial has 20 study locations across California, Florida, Hawaii, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Influenza

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00979251's enrollment target sits among peer trials

2 157th of 156 the lowest of 156 other Influenza trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Influenza trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00979251, the US trial registry maintained by the National Library of Medicine. NCT00979251 (small enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.